NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 258)
Posted On: 05/14/2020 3:39:46 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology
Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin*. Extremely versatile, the NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus. “Couple these properties with the extraordinary immunogenic properties and you have a potentially ‘game changing’ technology,” according to Dr. Joel Dobbs, a retired pharmaceutical industry executive, who is now Executive-in-Residence at UAB’s Collat School of Business. “This is a truly transitional technology that could change the way vaccines are made in the future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin*. Extremely versatile, the NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus. “Couple these properties with the extraordinary immunogenic properties and you have a potentially ‘game changing’ technology,” according to Dr. Joel Dobbs, a retired pharmaceutical industry executive, who is now Executive-in-Residence at UAB’s Collat School of Business. “This is a truly transitional technology that could change the way vaccines are made in the future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)